Abstract 190P
Background
Tislelizumab, a novel immune checkpoint inhibitor, holds promise as a treatment option for esophageal carcinoma. With limited effective therapies available for this aggressive malignancy, the emergence of immunotherapy represents a significant advancement in cancer treatment. Tislelizumab, by targeting the programmed death-1 (PD-1) pathway, has demonstrated encouraging results in clinical trials, showing potential for improved efficacy and tolerability compared to traditional chemotherapy regimens. This introduction explores the evolving role of tislelizumab in the management of esophageal carcinoma.
Methods
A systematic review and meta-analysis were done by searching in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, MEDLINE (including MEDLINE InProcess) (OvidSP), Web of Science, Embase (OvidSP), and Scopus databases. ROB2 Cochrane tools assessment for RCTs. In the analysis, we used RevMan Cochrane software.
Results
Pooling data from 4 studies for clinical success yielded an OR of 1.18 [95%CI: 0.58–2.41], indicating a significant difference (p = 0.03) between Tislelizumab and others. Heterogeneity was moderate (I2 = 26%). For recurrence (p = 0.042), pooling 3 studies produced an OR of 1.64 [95% CI: 0.64–4.22], with 44% heterogeneity. Mortality, pooled from 3 studies, resulted in an OR of 0.99 [95%CI: 0.56-1.75] (p = 0.002), with 14% heterogeneity.
Conclusions
In conclusion, Tislelizumab emerges as a promising treatment option for esophageal carcinoma, particularly in patients with advanced disease who have exhausted standard therapeutic modalities. Its efficacy in prolonging overall survival and improving disease control underscores its potential as a valuable addition to the treatment armamentarium for this aggressive malignancy. Despite potential adverse events, the benefits of Tislelizumab offer hope for improved outcomes and quality of life for patients with esophageal carcinoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.